Southampton Neuroscience Group, School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.
J Biol Chem. 2011 Dec 30;286(52):44512-20. doi: 10.1074/jbc.M111.307587. Epub 2011 Oct 7.
Neurodegenerative diseases are characterized by intra- and/or extracellular protein aggregation and oxidative stress. Intense attention has been paid to whether protein aggregation itself contributes to abnormal production of free radicals and ensuing cellular oxidative damage. Although this question has been investigated in the context of extracellular protein aggregation, it remains unclear whether protein aggregation inside cells alters the redox homeostasis. To address this, we have used in vitro and in vivo (cellular) models of Huntington disease, one of nine polyglutamine (poly(Q)) disorders, and examined the causal relationship among intracellular protein aggregation, reactive oxygen species (ROS) production, and toxicity. Live imaging of cells expressing a fragment of huntingtin (httExon1) with a poly(Q) expansion shows increased ROS production preceding cell death. ROS production is poly(Q) length-dependent and not due to the httExon 1 flanking sequence. Aggregation inhibition by the MW7 intrabody and Pgl-135 treatment abolishes ROS production, showing that increased ROS is caused by poly(Q) aggregation itself. To examine this hypothesis further, we determined whether aggregation of poly(Q) peptides in vitro generated free radicals. Monitoring poly(Q) protein aggregation using atomic force microscopy and hydrogen peroxide (H(2)O(2)) production over time in parallel we show that oligomerization of httEx1Q53 results in early generation of H(2)O(2). Inhibition of poly(Q) oligomerization by the single chain antibody MW7 abrogates H(2)O(2) formation. These results demonstrate that intracellular protein aggregation directly causes free radical production, and targeting potentially toxic poly(Q) oligomers may constitute a therapeutic target to counteract oxidative stress in poly(Q) diseases.
神经退行性疾病的特征是细胞内和/或细胞外蛋白质聚集和氧化应激。人们非常关注蛋白质聚集本身是否会导致自由基的异常产生,并进而导致细胞氧化损伤。尽管这个问题已经在细胞外蛋白质聚集的背景下进行了研究,但仍不清楚细胞内蛋白质聚集是否会改变氧化还原稳态。为了解决这个问题,我们使用了亨廷顿病的体外和体内(细胞)模型,亨廷顿病是九种多聚谷氨酰胺(poly(Q))疾病之一,研究了细胞内蛋白质聚集、活性氧(ROS)产生和毒性之间的因果关系。表达具有多聚谷氨酰胺(poly(Q))扩展的 huntingtin (httExon1) 片段的细胞的实时成像显示,细胞死亡前 ROS 产生增加。ROS 产生与 poly(Q)长度有关,而不是由于 httExon 1 侧翼序列。MW7 内体和 Pgl-135 治疗的聚集抑制消除了 ROS 产生,表明增加的 ROS 是由 poly(Q)聚集本身引起的。为了进一步检验这一假说,我们确定了体外多聚谷氨酰胺(poly(Q))肽的聚集是否产生自由基。使用原子力显微镜监测多聚谷氨酰胺(poly(Q))蛋白聚集,并同时监测过氧化氢(H(2)O(2))随时间的产生,我们表明 httEx1Q53 的寡聚化导致 H(2)O(2)的早期产生。单链抗体 MW7 抑制 poly(Q)寡聚化可消除 H(2)O(2)的形成。这些结果表明,细胞内蛋白质聚集直接导致自由基的产生,靶向潜在有毒的 poly(Q)寡聚体可能成为对抗 poly(Q)疾病中氧化应激的治疗靶点。